Ovarian stimulation for ovulatory disorders and assisted reproduction. From simple induction with oral medications till the controlled ovarian stimulation including different protocols.
Women's ovarian reserve decreases with age, resulting in infertility around age 40-50. Ovarian reserve reflects the number and quality of eggs and can be assessed through markers like FSH, estradiol, AMH, antral follicle count, and ovarian volume. AMH levels provide the best predictor of ovarian reserve as they fluctuate less than FSH and correlate with antral follicle counts. Both low (<0.5 ng/mL) and high (>2.5 ng/mL) AMH levels impact fertility and IVF outcomes. AMH testing is recommended for women over 30, those with risk factors for low reserve, or who are undergoing fertility treatments.
This document discusses the management of poor or hyper ovarian response in IVF treatment. It covers topics such as predicting ovarian reserve, definitions of poor response, protocols for poor and hyper responders, and techniques like coasting to help prevent ovarian hyperstimulation syndrome. Coasting, where gonadotropin administration is stopped but down regulation continued, is an effective way to prevent OHSS while still allowing for embryo retrieval and transfer. GnRH antagonist protocols may also help lower the risk of OHSS compared to long agonist protocols. There is no single best protocol, and treatments should be individualized based on patient factors and expectations.
This document contains information from Dr. Shashwat Jani regarding ovarian stimulation protocols for IUI. It discusses various stimulation options including clomiphene citrate, letrozole, gonadotropins, and combinations. It provides details on dosing, monitoring, and the advantages and disadvantages of different protocols. The goal of stimulation is to develop multiple follicles to improve pregnancy rates with IUI or develop a single follicle for anovulatory patients.
This document discusses gonadotropin ovarian stimulation. It begins by describing the different types of anovulation and ovarian stimulation protocols. It then discusses the different types of gonadotropin (Gnt) preparations including urinary and recombinant gonadotropins. Patient selection criteria and indications for ovarian stimulation are outlined. A low-dose step-up protocol is recommended to reduce risks of ovarian hyperstimulation syndrome and multiple pregnancies. Monitoring involves ultrasounds and bloodwork. Ovulation rates are over 90% while pregnancy rates range from 5-90% depending on factors. Complications include ovarian hyperstimulation syndrome and multiple pregnancies.
Ovulation Induction - Simplified - Dr Dhorepatil BharatiBharati Dhorepatil
What are factors to be considered
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of FSH & LH
Trigger
Luteal phase support
Pregnancy rate/cycle
This document discusses gonadotropin ovarian stimulation. It begins by describing the different types of anovulation and ovarian stimulation. It then discusses the different types of gonadotropins (Gnt) used for stimulation, including urinary and recombinant preparations. The document provides guidelines on patient selection, indications, contraindications, starting doses, protocols, monitoring, complications and conclusions regarding gonadotropin ovarian stimulation.
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANIDR SHASHWAT JANI
This document discusses the management of poor responders to ovarian stimulation. It defines poor responders according to the Bologna criteria as having two of the following: advanced age, a previous poor response, or abnormal biomarkers of ovarian reserve. It identifies various risk factors for poor response and stresses the importance of predicting response before treatment. It then discusses individualized controlled ovarian stimulation, including increasing gonadotropin doses, modifying GnRH analog protocols, using GnRH antagonists, and supplementing with growth hormone, estradiol, recombinant LH, and androgens to potentially improve outcomes for poor responders.
Women's ovarian reserve decreases with age, resulting in infertility around age 40-50. Ovarian reserve reflects the number and quality of eggs and can be assessed through markers like FSH, estradiol, AMH, antral follicle count, and ovarian volume. AMH levels provide the best predictor of ovarian reserve as they fluctuate less than FSH and correlate with antral follicle counts. Both low (<0.5 ng/mL) and high (>2.5 ng/mL) AMH levels impact fertility and IVF outcomes. AMH testing is recommended for women over 30, those with risk factors for low reserve, or who are undergoing fertility treatments.
This document discusses the management of poor or hyper ovarian response in IVF treatment. It covers topics such as predicting ovarian reserve, definitions of poor response, protocols for poor and hyper responders, and techniques like coasting to help prevent ovarian hyperstimulation syndrome. Coasting, where gonadotropin administration is stopped but down regulation continued, is an effective way to prevent OHSS while still allowing for embryo retrieval and transfer. GnRH antagonist protocols may also help lower the risk of OHSS compared to long agonist protocols. There is no single best protocol, and treatments should be individualized based on patient factors and expectations.
This document contains information from Dr. Shashwat Jani regarding ovarian stimulation protocols for IUI. It discusses various stimulation options including clomiphene citrate, letrozole, gonadotropins, and combinations. It provides details on dosing, monitoring, and the advantages and disadvantages of different protocols. The goal of stimulation is to develop multiple follicles to improve pregnancy rates with IUI or develop a single follicle for anovulatory patients.
This document discusses gonadotropin ovarian stimulation. It begins by describing the different types of anovulation and ovarian stimulation protocols. It then discusses the different types of gonadotropin (Gnt) preparations including urinary and recombinant gonadotropins. Patient selection criteria and indications for ovarian stimulation are outlined. A low-dose step-up protocol is recommended to reduce risks of ovarian hyperstimulation syndrome and multiple pregnancies. Monitoring involves ultrasounds and bloodwork. Ovulation rates are over 90% while pregnancy rates range from 5-90% depending on factors. Complications include ovarian hyperstimulation syndrome and multiple pregnancies.
Ovulation Induction - Simplified - Dr Dhorepatil BharatiBharati Dhorepatil
What are factors to be considered
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of FSH & LH
Trigger
Luteal phase support
Pregnancy rate/cycle
This document discusses gonadotropin ovarian stimulation. It begins by describing the different types of anovulation and ovarian stimulation. It then discusses the different types of gonadotropins (Gnt) used for stimulation, including urinary and recombinant preparations. The document provides guidelines on patient selection, indications, contraindications, starting doses, protocols, monitoring, complications and conclusions regarding gonadotropin ovarian stimulation.
MANAGEMENT OF POOR RESPONDERS IN IVF BY DR SHASHWAT JANIDR SHASHWAT JANI
This document discusses the management of poor responders to ovarian stimulation. It defines poor responders according to the Bologna criteria as having two of the following: advanced age, a previous poor response, or abnormal biomarkers of ovarian reserve. It identifies various risk factors for poor response and stresses the importance of predicting response before treatment. It then discusses individualized controlled ovarian stimulation, including increasing gonadotropin doses, modifying GnRH analog protocols, using GnRH antagonists, and supplementing with growth hormone, estradiol, recombinant LH, and androgens to potentially improve outcomes for poor responders.
Ovulation induction protocols for unexplained infertility new advances 2019 f...Anu Test Tube Baby Centre
1) Ovulation induction is used to treat unexplained infertility, where no specific cause is identified after basic evaluation. It aims to stimulate ovulation and increase the number of mature follicles available for fertilization.
2) Common protocols for ovulation induction in unexplained infertility include oral medications like clomiphene citrate or letrozole, injectable gonadotropins alone or with GnRH analogues, and IUI with or without ovarian stimulation.
3) While ovulation induction and IUI can help some women with unexplained infertility conceive, success rates decline significantly with increasing female age. Younger patients may benefit from several treatment cycles but many guidelines recommend proceeding directly to IVF after a year if
Ovarian Stimulation in IUI- Overview Sr. Jyoti BhaskarLifecare Centre
The document discusses ovarian stimulation protocols for intrauterine insemination (IUI) in subfertile women. It provides information on the rationale for controlled ovarian hyperstimulation (COH) in IUI, including increasing the number of eggs and overcoming subtle defects. The aim of COH is to recruit multiple follicles, control ovulation timing, prevent premature LH surges, time insemination, and increase pregnancy rates. Optimal stimulation results in 2-3 follicles ≥18-19mm in size and a thick, trilaminar endometrium. Gonadotropins are more effective than anti-estrogens like clomiphene citrate for IUI, and low
IVF – ICSI in PCOS DIFFICULTIES AND SOLUTIONS Dr. Sharda Jain Dr. Jyoti Bha...Lifecare Centre
This document discusses challenges and solutions for IVF-ICSI treatment in patients with polycystic ovarian syndrome (PCOS). It covers several topics, including:
1) Selection of PCOS patients for IVF by ensuring failure of first and second line ovulation induction treatments or laparoscopic ovarian drilling plus failure of three IUIs.
2) Pre-IVF workup including ruling out other conditions and optimizing general health by addressing obesity, insulin resistance, and other issues.
3) Pre-IVF treatments like weight loss, metformin use, oral contraceptives, and possible laparoscopic ovarian drilling to help with ovarian stimulation and prevent ovarian hyperstimulation syndrome (OHSS).
This document provides biographical information about Dr. Narendra Malhotra, an obstetrician and gynecologist from India. It lists his professional roles and accomplishments, which include being president of FOGSI, dean of ICMU, director of the Ian Donald School of Ultrasound, and editor of several medical books and journals. It also provides contact information for Malhotra Hospitals in Agra, India, where Dr. Malhotra practices and serves as a consultant for IVF procedures in several other cities.
This document discusses individualized controlled ovarian stimulation (I COS) protocols. It notes that conventional approaches use long agonist protocols with standard gonadotropin doses based on age. I COS allows for personalization based on ovarian reserve tests, biomarkers, and other factors to customize stimulation aims at moderate oocyte retrieval while increasing clinical pregnancy rates. Prediction models can be used to determine starting doses, protocols, and adjuvants based on a patient's ovarian response classification as poor, normal, or hyper responders.
The document discusses recent advances in controlled ovarian stimulation (COS) protocols for infertility treatment. It describes how recombinant gonadotropins are purer and safer than urinary gonadotropins, while having similar clinical efficacy. COS protocols now utilize GnRH antagonists to simplify treatment and decrease the risk of ovarian hyperstimulation syndrome compared to agonists. Overall, novel COS protocols incorporate recombinant gonadotropins and GnRH antagonists to provide patient-friendly stimulation with good outcomes.
This document discusses new developments in controlled ovarian stimulation (COS) protocols. It outlines several new forms of fertility drugs including long acting FSH, FSH biosimilars, and subcutaneous progestagens. It also describes new COS protocols such as those using fewer injections, flexibility in start dates, dual stimulation, and individualizing FSH dosing to prevent ovarian hyperstimulation syndrome. The document concludes that while further research is still needed, these new drugs and protocols provide valuable options for increasing flexibility and optimizing outcomes in ART treatment.
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiBharati Dhorepatil
What are important factors to be considered important
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of LH
Trigger
Luteal phase support
Pregnancy rate/cycle
IUI is a basic but effective form of fertiltiy treatment and can be a viable alternative to the expensive IVF / test tube baby treatment that is normally advised.
This presentation will be very useful for the practising gynecologists, IVF specialists and General practitioners who perform IUI.
Even patients on going through this presentation will be more educated about iui.
Please reach out to me on 9833032120 by whatsapp / Telegram or phone call or email on dalalsj@gmail.com for further details / treatment options.
Number of oocytes and progesterone levels in IVF: Do they matter?Sandro Esteves
- The document summarizes research on factors that influence IVF success rates, including the number of oocytes retrieved and progesterone levels.
- It finds that retrieving around 15 oocytes optimizes live birth rates, and that recombinant FSH preparations yield more oocytes than other gonadotropins.
- While progesterone levels on the day of hCG administration correlate with the number of oocytes, there is no clear evidence that certain progesterone levels negatively impact pregnancy rates, especially with adequate embryos for freezing and future transfers.
- Considering cumulative live birth rates from multiple transfer cycles is important to properly assess IVF success rates and outcomes. Optimizing oocyte yield, embryo culture, vitrification techniques, and performing
This document discusses luteal phase physiology following GnRH agonist (GnRHa) trigger versus HCG trigger for final oocyte maturation in IVF/ICSI cycles. It compares the differences in luteal steroid levels and LH activity between the two triggers. The safety and efficacy of GnRHa trigger is examined, including prevention of OHSS and effects on oocyte maturation and implantation. Limitations of GnRHa trigger in supporting the luteal phase are outlined, as well as various approaches to optimal luteal phase support, including exogenous steroids or stimulating endogenous support with low dose HCG or recombinant LH. The document concludes that with appropriate modified luteal phase support, reproductive outcomes after GnRHa trigger can
Individualisation of controlled ovarian stimulationAboubakr Elnashar
This document discusses individualizing controlled ovarian stimulation (COS) protocols based on a patient's ovarian reserve. It describes various ovarian reserve tests (ORTs) like AMH and AFC levels that can categorize patients' responses. Prediction models incorporating multiple factors are presented to anticipate poor or high responses and tailor gonadotropin starting doses. Treatment strategies for different POSEIDON patient groups aim to maximize oocyte yield, including increasing gonadotropin doses or adding medications like recombinant LH. Dual stimulation protocols within one cycle are also proposed.
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...Lifecare Centre
Letrozole is an aromatase inhibitor that has been shown to be effective for ovulation induction. It works by decreasing estrogen production in the ovaries. Some advantages of letrozole over clomiphene citrate include shorter half-life, lack of anti-estrogenic effects on the endometrium and cervical mucus, increased uterine blood flow, and lower risks of multiple pregnancy and OHSS. Common side effects include hot flashes and headaches. Guidelines from several medical societies recommend letrozole as a first-line treatment for ovulation induction in women with PCOS. The starting dose is typically 2.5 mg daily for 5 days, but step-up protocols have also shown effectiveness.
Dr. Sunita Chandra, Chairperson & Director-Rajendra Nagar Hospital & IVF Centre and Mopheus Lucknow Fertility Centre gave the talk on IVF PREGNANCY at webinar on March 27,2021
This document discusses poor responders in IVF treatment. It defines poor responders based on the Bologna criteria as women aged 40 or older, or with another risk factor, who have produced 3 or fewer oocytes in a conventional stimulation protocol or have an abnormal ovarian reserve test. The document discusses using lower gonadotropin doses (150-450 IU) for poor responders to reduce risks while still achieving pregnancy. It also analyzes the use of long agonist versus antagonist protocols, finding the long agonist protocol may increase maturity and lower cancellation rates for expected poor responders. Finally, it presents a study showing double stimulation protocols over 4 weeks can produce twice as many oocytes and blastocysts for poor
This document discusses different types of ovarian stimulation and anovulation. It describes four types of anovulation classified by the WHO and treatments for each. It covers controlled ovarian stimulation, types of gonadotropins used for stimulation including urinary and recombinant preparations, and protocols for use of clomiphene citrate, aromatase inhibitors, metformin, and gonadotropins in treatment. Adjuvant treatments to improve outcomes with clomiphene citrate are also discussed.
This document provides information about various low-cost and minimal stimulation protocols for in vitro fertilization (IVF) that can help make IVF more affordable and accessible. It discusses protocols that use oral medications instead of or in combination with injectable gonadotropins to stimulate egg development, which can significantly reduce costs while still achieving reasonable success rates. Specific protocols mentioned include the use of clomiphene citrate alone or with low-dose gonadotropins, protocols from Japan and China, and the use of dydrogesterone. The document emphasizes developing protocols that can obtain a few high-quality eggs with fewer injections and less risk of ovarian hyperstimulation syndrome to balance effectiveness with reducing costs and complications.
Ovulation induction protocols for unexplained infertility new advances 2019 f...Anu Test Tube Baby Centre
1) Ovulation induction is used to treat unexplained infertility, where no specific cause is identified after basic evaluation. It aims to stimulate ovulation and increase the number of mature follicles available for fertilization.
2) Common protocols for ovulation induction in unexplained infertility include oral medications like clomiphene citrate or letrozole, injectable gonadotropins alone or with GnRH analogues, and IUI with or without ovarian stimulation.
3) While ovulation induction and IUI can help some women with unexplained infertility conceive, success rates decline significantly with increasing female age. Younger patients may benefit from several treatment cycles but many guidelines recommend proceeding directly to IVF after a year if
Ovarian Stimulation in IUI- Overview Sr. Jyoti BhaskarLifecare Centre
The document discusses ovarian stimulation protocols for intrauterine insemination (IUI) in subfertile women. It provides information on the rationale for controlled ovarian hyperstimulation (COH) in IUI, including increasing the number of eggs and overcoming subtle defects. The aim of COH is to recruit multiple follicles, control ovulation timing, prevent premature LH surges, time insemination, and increase pregnancy rates. Optimal stimulation results in 2-3 follicles ≥18-19mm in size and a thick, trilaminar endometrium. Gonadotropins are more effective than anti-estrogens like clomiphene citrate for IUI, and low
IVF – ICSI in PCOS DIFFICULTIES AND SOLUTIONS Dr. Sharda Jain Dr. Jyoti Bha...Lifecare Centre
This document discusses challenges and solutions for IVF-ICSI treatment in patients with polycystic ovarian syndrome (PCOS). It covers several topics, including:
1) Selection of PCOS patients for IVF by ensuring failure of first and second line ovulation induction treatments or laparoscopic ovarian drilling plus failure of three IUIs.
2) Pre-IVF workup including ruling out other conditions and optimizing general health by addressing obesity, insulin resistance, and other issues.
3) Pre-IVF treatments like weight loss, metformin use, oral contraceptives, and possible laparoscopic ovarian drilling to help with ovarian stimulation and prevent ovarian hyperstimulation syndrome (OHSS).
This document provides biographical information about Dr. Narendra Malhotra, an obstetrician and gynecologist from India. It lists his professional roles and accomplishments, which include being president of FOGSI, dean of ICMU, director of the Ian Donald School of Ultrasound, and editor of several medical books and journals. It also provides contact information for Malhotra Hospitals in Agra, India, where Dr. Malhotra practices and serves as a consultant for IVF procedures in several other cities.
This document discusses individualized controlled ovarian stimulation (I COS) protocols. It notes that conventional approaches use long agonist protocols with standard gonadotropin doses based on age. I COS allows for personalization based on ovarian reserve tests, biomarkers, and other factors to customize stimulation aims at moderate oocyte retrieval while increasing clinical pregnancy rates. Prediction models can be used to determine starting doses, protocols, and adjuvants based on a patient's ovarian response classification as poor, normal, or hyper responders.
The document discusses recent advances in controlled ovarian stimulation (COS) protocols for infertility treatment. It describes how recombinant gonadotropins are purer and safer than urinary gonadotropins, while having similar clinical efficacy. COS protocols now utilize GnRH antagonists to simplify treatment and decrease the risk of ovarian hyperstimulation syndrome compared to agonists. Overall, novel COS protocols incorporate recombinant gonadotropins and GnRH antagonists to provide patient-friendly stimulation with good outcomes.
This document discusses new developments in controlled ovarian stimulation (COS) protocols. It outlines several new forms of fertility drugs including long acting FSH, FSH biosimilars, and subcutaneous progestagens. It also describes new COS protocols such as those using fewer injections, flexibility in start dates, dual stimulation, and individualizing FSH dosing to prevent ovarian hyperstimulation syndrome. The document concludes that while further research is still needed, these new drugs and protocols provide valuable options for increasing flexibility and optimizing outcomes in ART treatment.
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiBharati Dhorepatil
What are important factors to be considered important
Ovarian reserve
Previous ovarian response
Basic hormone profile
Role of LH
Trigger
Luteal phase support
Pregnancy rate/cycle
IUI is a basic but effective form of fertiltiy treatment and can be a viable alternative to the expensive IVF / test tube baby treatment that is normally advised.
This presentation will be very useful for the practising gynecologists, IVF specialists and General practitioners who perform IUI.
Even patients on going through this presentation will be more educated about iui.
Please reach out to me on 9833032120 by whatsapp / Telegram or phone call or email on dalalsj@gmail.com for further details / treatment options.
Number of oocytes and progesterone levels in IVF: Do they matter?Sandro Esteves
- The document summarizes research on factors that influence IVF success rates, including the number of oocytes retrieved and progesterone levels.
- It finds that retrieving around 15 oocytes optimizes live birth rates, and that recombinant FSH preparations yield more oocytes than other gonadotropins.
- While progesterone levels on the day of hCG administration correlate with the number of oocytes, there is no clear evidence that certain progesterone levels negatively impact pregnancy rates, especially with adequate embryos for freezing and future transfers.
- Considering cumulative live birth rates from multiple transfer cycles is important to properly assess IVF success rates and outcomes. Optimizing oocyte yield, embryo culture, vitrification techniques, and performing
This document discusses luteal phase physiology following GnRH agonist (GnRHa) trigger versus HCG trigger for final oocyte maturation in IVF/ICSI cycles. It compares the differences in luteal steroid levels and LH activity between the two triggers. The safety and efficacy of GnRHa trigger is examined, including prevention of OHSS and effects on oocyte maturation and implantation. Limitations of GnRHa trigger in supporting the luteal phase are outlined, as well as various approaches to optimal luteal phase support, including exogenous steroids or stimulating endogenous support with low dose HCG or recombinant LH. The document concludes that with appropriate modified luteal phase support, reproductive outcomes after GnRHa trigger can
Individualisation of controlled ovarian stimulationAboubakr Elnashar
This document discusses individualizing controlled ovarian stimulation (COS) protocols based on a patient's ovarian reserve. It describes various ovarian reserve tests (ORTs) like AMH and AFC levels that can categorize patients' responses. Prediction models incorporating multiple factors are presented to anticipate poor or high responses and tailor gonadotropin starting doses. Treatment strategies for different POSEIDON patient groups aim to maximize oocyte yield, including increasing gonadotropin doses or adding medications like recombinant LH. Dual stimulation protocols within one cycle are also proposed.
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...Lifecare Centre
Letrozole is an aromatase inhibitor that has been shown to be effective for ovulation induction. It works by decreasing estrogen production in the ovaries. Some advantages of letrozole over clomiphene citrate include shorter half-life, lack of anti-estrogenic effects on the endometrium and cervical mucus, increased uterine blood flow, and lower risks of multiple pregnancy and OHSS. Common side effects include hot flashes and headaches. Guidelines from several medical societies recommend letrozole as a first-line treatment for ovulation induction in women with PCOS. The starting dose is typically 2.5 mg daily for 5 days, but step-up protocols have also shown effectiveness.
Dr. Sunita Chandra, Chairperson & Director-Rajendra Nagar Hospital & IVF Centre and Mopheus Lucknow Fertility Centre gave the talk on IVF PREGNANCY at webinar on March 27,2021
This document discusses poor responders in IVF treatment. It defines poor responders based on the Bologna criteria as women aged 40 or older, or with another risk factor, who have produced 3 or fewer oocytes in a conventional stimulation protocol or have an abnormal ovarian reserve test. The document discusses using lower gonadotropin doses (150-450 IU) for poor responders to reduce risks while still achieving pregnancy. It also analyzes the use of long agonist versus antagonist protocols, finding the long agonist protocol may increase maturity and lower cancellation rates for expected poor responders. Finally, it presents a study showing double stimulation protocols over 4 weeks can produce twice as many oocytes and blastocysts for poor
This document discusses different types of ovarian stimulation and anovulation. It describes four types of anovulation classified by the WHO and treatments for each. It covers controlled ovarian stimulation, types of gonadotropins used for stimulation including urinary and recombinant preparations, and protocols for use of clomiphene citrate, aromatase inhibitors, metformin, and gonadotropins in treatment. Adjuvant treatments to improve outcomes with clomiphene citrate are also discussed.
This document provides information about various low-cost and minimal stimulation protocols for in vitro fertilization (IVF) that can help make IVF more affordable and accessible. It discusses protocols that use oral medications instead of or in combination with injectable gonadotropins to stimulate egg development, which can significantly reduce costs while still achieving reasonable success rates. Specific protocols mentioned include the use of clomiphene citrate alone or with low-dose gonadotropins, protocols from Japan and China, and the use of dydrogesterone. The document emphasizes developing protocols that can obtain a few high-quality eggs with fewer injections and less risk of ovarian hyperstimulation syndrome to balance effectiveness with reducing costs and complications.
This document discusses several complex cases involving intrauterine insemination (IUI). It describes patient histories, stimulation protocols, semen analysis results, and challenges that arose during IUI procedures. The panelists discuss options for each case, including risks of ovarian hyperstimulation, limitations of IUI for endometriosis patients, preventing premature ovulation, difficult insemination techniques, and using ultrasound guidance. The document provides guidance on managing risks and complications to optimize IUI success rates.
Ovarian Hyperstimulation Syndrome(OHSS), is a Rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy where a patient's ovaries become swollen and fluid builds up around her abdomen
This document discusses various aspects of ovarian stimulation for infertility treatment. It provides an overview of infertility facts and causes, methods for assessing ovarian reserve, and different protocols for ovarian stimulation including clomiphene, letrozole, and gonadotropins. It also discusses indications for and outcomes of ovarian stimulation combined with intrauterine insemination.
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayiabayomi ajayi
This document discusses methods for final oocyte maturation in IVF treatment. It notes that human chorionic gonadotropin (HCG) has traditionally been used but gonadotropin-releasing hormone (GnRH) agonists can also be used to reduce the risk of ovarian hyperstimulation syndrome (OHSS). While GnRH agonists prevent OHSS, they are associated with lower pregnancy rates. However, combining a GnRH agonist trigger with low-dose HCG or vitrification of all embryos may optimize pregnancy rates while still preventing OHSS. The optimal luteal phase support when using a GnRH agonist trigger remains an area of ongoing research.
Dr. Laxmi Shrikhande has had an illustrious career in obstetrics and gynecology. She has held numerous leadership positions including Chairperson for ICOG, national corresponding editor, and founder and president of various medical organizations. She has received several awards for her contributions to women's health. Her career highlights include over 450 guest lectures, 31 national publications, and sensitizing over 200,000 adolescents on health issues. She currently serves as the medical director of Shrikhande Fertility Clinic in Nagpur, Maharashtra.
1) The panel discussion focused on the diagnosis and management of PCOS, discussing two patient cases.
2) For the first patient, the panel recommended Letrozole as the first line ovulation induction drug. For the second patient who failed Letrozole, the panel recommended IVF due to failed ovulation induction and associated male factor infertility.
3) The panel also discussed monitoring protocols, use of adjuvants like metformin, and measures to reduce OHSS for both patients undergoing ovulation induction and IVF.
This document discusses the authors' experience with ovarian hyperstimulation syndrome (OHSS) in 580 in vitro fertilization (IVF) cycles. It provides information on:
- The incidence of mild, moderate, and severe OHSS in their IVF cycles.
- The pathophysiology of OHSS and how it is classified as early or late depending on timing.
- Their findings that OHSS does not occur without hCG trigger and symptoms resolve within 10-12 days without pregnancy.
- Strategies for preventing OHSS including GnRH antagonist protocols, GnRH agonist trigger, cryopreservation of embryos, and use of metformin in PCOS patients.
- Their proposed "
Medical managment of ovarian hyperstimulationLifecare Centre
This document discusses the authors' experience with ovarian hyperstimulation syndrome (OHSS) in 580 in vitro fertilization (IVF) cycles. It provides information on:
- The incidence of mild, moderate, and severe OHSS in their IVF cycles.
- The classification of early versus late OHSS and risk factors associated with each.
- Their findings that OHSS does not develop without hCG administration and is more severe in conception cycles.
- Strategies for preventing OHSS including GnRH antagonist protocols, GnRH agonist triggering, cryopreservation of all embryos, and metformin use for high-risk patients.
- Methods for managing OHSS such as pain relief,
Dr. Sunita Chandra discusses improving results in IUI (intrauterine insemination). IUI involves sperm processing and placement into the uterine cavity with a catheter. IUI can be effective for infertility due to ovulation disorders, unexplained infertility, and mild male factor infertility. The success of IUI depends on factors like age, ovarian reserve, patient selection, ovulation induction, cycle monitoring and timing, and luteal phase support. Dr. Chandra provides guidance on patient workup, stimulation protocols, trigger timing, and IUI timing to optimize IUI outcomes.
This study compared ovarian response, oocyte and embryo quality, and pregnancy rates between PCOS and non-PCOS patients undergoing IVF. The main findings were:
1. PCOS patients had more follicles on the day of retrieval but fewer mature oocytes and top-quality embryos compared to non-PCOS patients.
2. The recovery rates of oocytes and mature oocytes per follicle were lower in the PCOS group.
3. Pregnancy rates were comparable between the two groups despite differences in ovarian response and embryo quality.
This document discusses infertility and polycystic ovary syndrome (PCOS). It defines PCOS and outlines its diagnosis criteria. PCOS is diagnosed based on somatic or lab indicators of hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology, while excluding other disorders. Treatment options for PCOS include weight loss, exercise, clomiphene, aromatase inhibitors, metformin, and gonadotropins. Long-term management may involve birth control pills, metformin therapy, and lifestyle changes to reduce risks of weight gain, hyperandrogenism, and cardiac or metabolic diseases.
This document discusses infertility, its causes and treatments including assisted reproductive technologies. It notes that infertility has risen 50% in India over recent decades with 46% of Indians aged 31-40 requiring medical help to conceive. Both male and female factors contribute nearly equally to infertility. After evaluating causes for each couple, treatments may include ovulation induction, intrauterine insemination, in vitro fertilization, intracytoplasmic sperm injection or use of donor gametes. New assisted reproduction techniques have increased options but the best treatment depends on the individual infertility factors involved.
COMPLICATIONS OF ASSISTED REPROUCTIVE TECHIQUESDrRokeyaBegum
Assisted reproductive techniques (ART) such as IVF and ICSI can help treat infertility but also carry several risks. A major complication is ovarian hyperstimulation syndrome (OHSS) which can range from mild to severe/critical. Prevention strategies include using the lowest effective drug doses, coasting, GnRH agonist triggering, and cryopreserving all embryos. Other risks include multiple pregnancies, preterm birth, and pregnancy complications. Careful patient selection and monitoring can help reduce risks from ART.
Medical Management of Ovarian Hyperstimulation Syndrome (OHSS) In 1500 IUI...Lifecare Centre
This document discusses the medical management of ovarian hyperstimulation syndrome (OHSS) in 1500 intrauterine insemination (IUI) cycles. It notes that OHSS is an iatrogenic complication caused by the use of human chorionic gonadotropin (HCG) for ovarian induction. The incidence of OHSS in IUI cycles is reported to be lower than in IVF cycles, with mild to moderate cases being most common. Guidelines for preventing, diagnosing, and treating OHSS in IUI cycles focus on identifying at-risk patients, using a mild stimulation protocol with close monitoring, potentially withholding HCG trigger, and modifying the luteal phase with cabergoline and/or GnRH antagon
This document discusses various microorganisms that cause infections, including their classification, structures, mechanisms of infection, and treatments. It covers viruses, bacteria, fungi, and prions. For bacteria specifically, it describes their shapes (cocci, bacilli), staining properties, cell wall structures, toxin production, and antibiotic mechanisms. Common pathogenic bacteria mentioned include Streptococcus, Staphylococcus, Clostridium, Bacillus, Corynebacterium, and others. The document provides detailed information on microbial infections and antimicrobial therapies.
This document discusses obstetric and gynecological infections, focusing on HPV and chlamydia. It provides details on the anatomy, transmission, presentation, diagnosis and treatment of HPV and chlamydia. For HPV, it describes the different types and their cancer risks. It outlines screening and vaccination recommendations. For chlamydia, it discusses risk factors, complications of untreated infection, testing approaches and recommended antibiotic regimens. The goal is to raise awareness of these common infections and provide clinical guidance for management.
This document discusses pre-invasive disease of the female genital tract, including the cervix, vulva, and vagina. It covers the spectrum of intraepithelial neoplasia, epidemiology, risk factors like HPV infection, screening recommendations, diagnostic tools like liquid-based cytology, and management approaches like local excision. The document provides clinical guidance on evaluating and treating pre-malignant lesions of the lower female genital tract.
This document provides information on cervical cancer, including epidemiology, risk factors, pathology, staging, clinical presentation, diagnostic evaluation, and treatment. Some key points:
- Cervical cancer is the fourth most common cancer in women worldwide. Incidence has decreased with cervical screening.
- Squamous cell carcinoma and adenocarcinoma account for most cases. Risk factors include HPV infection, early sexual activity, and oral contraceptive use.
- Staging involves clinical exam, imaging, and pathology to assess tumor size and extent. The 2018 FIGO staging system allows use of imaging and pathology findings.
- Treatment depends on disease stage, age, fertility desires, and includes surgery, radiotherapy, or chemor
This document discusses venous thromboembolism (VTE) during pregnancy and the postpartum period. It notes that VTE is one of the leading causes of maternal mortality. Risk factors for VTE include inherited or acquired thrombophilias, prior VTE, surgery, trauma, immobility, inflammation, malignancy, estrogens, and atherosclerosis. Pregnancy induces a hypercoagulable state due to increased clotting factors and decreased anticoagulant activity. The risk of VTE is highest in the postpartum period, especially the first few weeks. Guidelines are provided for thromboprophylaxis based on a woman's risk factor score.
1) Up to one-third of pregnancies are unintended in the UK and unintended pregnancy is associated with poorer health outcomes for both mother and baby. Contraception allows for planning of pregnancies and general health optimization.
2) Various contraceptive methods are available through the NHS including pills, implants, IUDs and barrier methods. Their mechanisms of action include preventing ovulation, fertilization or implantation.
3) When assessing and prescribing contraception, factors like medical history, risks and benefits must be considered. Methods have varying typical and perfect use failure rates.
The document discusses the risks associated with in vitro fertilization (IVF) procedures. It covers risks related to ovarian stimulation, egg retrieval, embryo transfer, pregnancy outcomes, and long-term effects. Specific complications addressed include ovarian hyperstimulation syndrome (OHSS), pelvic infection, bleeding, ovarian torsion, birth defects, miscarriage, ectopic pregnancy, and multiple pregnancy. Prevention strategies and treatment options are provided for several of the risks.
This document discusses menopause and hormone replacement therapy (HRT). It defines menopause and the stages surrounding it, including peri-menopause and post-menopause. It describes the pathophysiology of menopause and associated symptoms in the acute, medium-term, and long-term periods. These include hot flashes, vaginal dryness, urinary problems, and increased risk of osteoporosis and cardiovascular disease. The document outlines recommendations for diagnosing menopause and managing related symptoms through lifestyle changes, counseling, and HRT or alternatives when symptoms are severe. HRT is noted as the most effective treatment for estrogen deficiency symptoms.
This document discusses reproductive endocrinology and the hormonal regulation of the menstrual cycle. It describes the hypothalamic-pituitary-ovarian axis and the roles of hormones such as GnRH, FSH, LH, estradiol, and progesterone in follicular development, ovulation, and the luteal phase. It also covers puberty and precocious puberty, mechanisms of contraception, and disorders of sexual development.
Sex differentiation occurs through genetic and hormonal factors. Hyperandrogenism results from excess androgen production or sensitivity and causes hirsutism, acne and other virilizing symptoms. Polycystic ovary syndrome (PCOS) is the most common cause of hyperandrogenism, affecting around 10% of women. PCOS is diagnosed using the Rotterdam criteria of hyperandrogenism, ovarian dysfunction and polycystic ovaries on ultrasound. Women with PCOS have increased risks of metabolic complications like diabetes and cardiovascular disease. Evaluation and management focuses on controlling symptoms, screening for metabolic risks, and lifestyle modifications.
This document discusses obstetric and gynecological infections, focusing on HPV and Chlamydia. It provides details on the anatomy, pathogenesis, transmission, symptoms, screening, and treatment of HPV and Chlamydia infections. HPV is commonly transmitted sexually and can cause genital warts or lead to cancers like cervical cancer if a persistent infection is not cleared. Chlamydia is an obligate intracellular bacterium that often causes no symptoms but can lead to complications like pelvic inflammatory disease and infertility if left untreated. Screening programs and antibiotic treatment are discussed as ways to diagnose and manage HPV and Chlamydia infections.
This document discusses various microorganisms that cause infections including viruses, bacteria, fungi and protozoa. It provides details on the classification, morphology and mechanisms of different bacteria based on their gram staining reaction and other features. Specific pathogenic bacteria are discussed in depth including their related diseases. Treatment options for various infections are mentioned including different classes of antibiotics and their mechanisms of action.
This document discusses recurrent pregnancy loss, providing definitions and discussing possible causes and management approaches. It defines recurrent pregnancy loss as the loss of two or more pregnancies and notes that a cause can be found in only 60% of cases. Possible causes discussed include advanced maternal age, chromosomal abnormalities, immunological factors like antiphospholipid syndrome, anatomical issues, infections, hormonal imbalances, environmental exposures, personal habits, stress, and idiopathic causes. Management may involve treating explainable causes as well as addressing prognostic factors for future live births.
The document discusses antenatal care and provides guidelines on various aspects of care during pregnancy. It outlines the aims of antenatal care including screening for maternal and fetal complications and assessing well-being. It provides advice on lifestyle factors such as nutrition, exercise, travel, and discusses vitamin supplements that should be taken. Risks of conditions like preeclampsia are mentioned. Health professionals involved in care and documentation standards are also summarized.
Venothromboembolism during pregnancy and puerperiumAhmed Elbohoty
This document discusses venous thromboembolism (VTE) during pregnancy and the postpartum period. It notes that VTE is a leading cause of maternal mortality in the UK. Risk factors for VTE include both inherited and acquired thrombophilias, prior VTE, surgery, immobility, inflammation, and estrogen exposure during pregnancy. Guidelines are provided for thromboprophylaxis based on a woman's number and types of risk factors. Management of high-risk conditions like antithrombin deficiency is also discussed.
This document discusses thyroid disorders and their effects on reproduction and pregnancy. Some key points:
- Thyroid diseases are very common in women of childbearing age and can affect fertility, maternal health, and fetal development.
- Hypothyroidism is more prevalent than hyperthyroidism and has implications for pregnancy outcomes. Thyroid autoimmunity is also increased in subfertile populations.
- Both overt and subclinical hypothyroidism are associated with menstrual irregularities and reduced fertility, implantation, and live birth rates. Treatment of hypothyroidism can improve these outcomes.
Thrombocytopenia, or low platelet count, occurs in 8-10% of pregnancies. It is usually mild and benign, with the most common causes being gestational thrombocytopenia or preeclampsia. More severe cases require differential diagnosis between conditions like HELLP syndrome, thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), antiphospholipid antibody syndrome (APS), or viral infections. Management may include corticosteroids, intravenous immunoglobulin (IVIG), or platelet transfusion depending on severity. Close monitoring is important during pregnancy and delivery due to risks of hemorrhage.
This document discusses various skin conditions that can occur during pregnancy. It begins by outlining physiological skin changes caused by hormonal factors, such as increased pigmentation, vascular changes, and pruritis. It then describes several important pathological skin diseases of pregnancy, including intrahepatic cholestasis of pregnancy, atopic eruption of pregnancy, polymorphic eruption of pregnancy, and pemphigoid gestationis. These conditions can cause pruritis, rashes and in severe cases threaten the health of the mother and fetus. The document provides details on presentation, diagnosis, and management of these key pregnancy-related skin diseases.
This document discusses renal diseases in pregnancy. It begins by noting that urinary tract infections are common in pregnancy and can cause maternal and fetal complications. It then discusses how renal disease can be a risk factor for preeclampsia and fetal growth restriction. The document provides details on renal adaptation during pregnancy, management of urinary tract infections and pyelonephritis, renal stones, and the effects of pregnancy on pre-existing renal impairment. It emphasizes the importance of pre-pregnancy counseling and management for women with renal disease.
This document discusses psychiatric disorders in pregnant and lactating women. It provides information on how pregnancy can impact mental health and psychiatric disorders. Key points include how psychiatric disorders and medications can affect pregnancy and the fetus. It emphasizes the importance of screening and predicting mental health issues during pregnancy and postpartum. The document also discusses managing different mental disorders throughout pregnancy, delivery, and lactation.
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Jim Jacob Roy
In this presentation , SBP ( spontaneous bacterial peritonitis ) , which is a common complication in patients with cirrhosis and ascites is described in detail.
The reference for this presentation is Sleisenger and Fordtran's Gastrointestinal and Liver Disease Textbook ( 11th edition ).
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
This presentation gives information on the pharmacology of Prostaglandins, Thromboxanes and Leukotrienes i.e. Eicosanoids. Eicosanoids are signaling molecules derived from polyunsaturated fatty acids like arachidonic acid. They are involved in complex control over inflammation, immunity, and the central nervous system. Eicosanoids are synthesized through the enzymatic oxidation of fatty acids by cyclooxygenase and lipoxygenase enzymes. They have short half-lives and act locally through autocrine and paracrine signaling.
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14...Donc Test
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
TEST BANK For Brunner and Suddarth's Textbook of Medical-Surgical Nursing, 14th Edition (Hinkle, 2017) Verified Chapter's 1 - 73 Complete.pdf
2. ILOs
• To Understand the basic endocrinology of ovulation
• To identify the indications of ovulation inductions
• To be able to use ovulation induction medicines in an effective
and safe way
• To individualize protocol of induction according to patient
parameters
• To use luteal phase support in an effective way
• To highlight the potential complications of ovulation induction.
3/18/20ELBOHOTY
6. Why do we use ovulation induction?
!Treatment of Chronic Anovulation
!IUI
!IVF/ICSI
3/18/20ELBOHOTY
7. Is ovulation induction alone an effective
treatment of unexplained infertility ?
No
3/18/20
Elbohoty et al., 2017; Crosignani et al., 1991; Guzick et al., 1999; Goverde et al., 2000; Aboulghar et al., 2003
ELBOHOTY
8. Aim Of Ovarian stimulation
3/18/20
For Anovulation or IUI For IVF-ICSI Freeze all
Monofollicular Multifollicular
ELBOHOTY
11. Anovulation Types
3/18/20
WHO Type I
WHO Type II
WHO Type III
WHO Type IV
Criteria/Tests
Mid-luteal serum progesterone
EtiologyClassification
↓ ↓ ↓ ↓ FSH, LH, E2.
LH <1.2 IU/L
Normal prolactin
hypothalamic
pituitary failure
Group I
10%
2 out of 3 after exclusion of other
endorcinopathy
• Oligo or anovulation.
• Hyperandrogenism
• PCOM
hypothalamic-
pituitary-ovarian
dysfunction
PCOS
Group II
75-80%
High FSH, LH
Low E2
Premature
ovarian
insufficiency.
Group III
5-10 %
prolactin> 500 mU/L
↓ ↓ ↓ ↓ FSH, LH, E2
Hyperprolactinemia
CAHGroup IV
5-10%ELBOHOTY
12. Aim of the treatment of chronic
anovulation:
!Management of any associated
health problem
!Monoovulation.
3/18/20(ESHRE Capri Workshop Group, 2003). ELBOHOTY
13. Causes
Weight loss
Exercise
Psychological stress
Pituitary damage:Sheehan's
syndrome,Hemosiderosis (Thalathemia)
Tumours, Cranial irradiation Head injuries
Chronic illness
Genetic, e.g. Kallmans syndrome
Idiopathic
Hypogonadotropic Anovulation
WHO I
↓ ↓ ↓ ↓ FSH, LH, E2
Normal prolactin
3/18/20 ELBOHOTY
14. Management
• Identifying the cause, exclude intracranial lesion e.g. MRI.
• Increasing the BMI if it is ≤19
• Moderating exercise levels if they undertake high levels of exercise.
• HMG versus rFSH+rLH (STEP UP Approach) aiming for monofollicular development
• GnRH analouges ?!
• Long term care of bone
3/18/20
75 IU HMG or rFSH+rLH
/day
Cycle
D
112.5 IU
250 μg hCG21th D
14th D2nd day
>18 mm
150 IU
TVUS
TVUS
TVUS
TVUS
Luteal support
ELBOHOTY
15. Diagnosis & Management
Before the age of 40 years
Two FSH levels > 30 iu/ml at an interval of at least 1
month.
Search for the cause: Karyotyping, …
Spontaneous resumption of ovulation in 5 %
Egg donation
Manage consequences: HRT
Causes
Idiopathic 88%
Chromosomal abnormalities 9%
Iatrogenic causes 2.1 %
Autoimmune causes 0.8%
Bachelot et al., 2009
WHO Type III
Premature Ovarian Insufficiency
3/18/20 ELBOHOTY
17. •Repeat Prolactin level.
Exclude pregnancy, check
medicines hypothyroidism, ….
•Treat the cause
•S.prolactin>1000mIU/L: MRI
•Micro or Macroadenoma:
Dopamine agonists:
Cabergoline 0.25 - 1 mg twice
weekly
3/18/20
Management
ELBOHOTY
18. WHO Type II
The most common form of
ovulatory dysfunction.
80% are due to polycystic
ovarian Syndrome
(Broekmans et al., 2006; NEJM, 2016).
3/18/20ELBOHOTY
19. Diagnosis of PCOs
• Two of the following criteria requested:
1) Oligo or anovulation.
2) Clinical and/or biochemical signs of hyperandrogenism
3) PCOM :
• Using TVS with a frequency ≥ 8MHz: a follicle number per ovary of > 20 and/or an ovarian volume ≥ 10ml
• Using older technology or TAS: an ovarian volume ≥ 10ml on either ovary.
3/18/20 (ESHRE, 2018; ESHRE/ASRM, 2004)
Other causes of menstrual cycle disturbance or androgen excess should be excluded.
ELBOHOTY
20. 3/18/20
Different phenotypes
Type 1,2 & 4 are anovulatory
Phenotype 1 (classic PCOS) 62.4%
• Clinical and/or biochemical evidence of hyperandrogenism
• Evidence of oligo-anovulation
• Ultrasonographic evidence of a polycystic ovary
Phenotype 2 (Essential NIH Criteria) 8.6%
• Clinical and/or biochemical evidence of hyperandrogenism
• Evidence of oligo-anovulation
Phenotype 3 (ovulatory PCOS) 11 %
• Clinical and/or biochemical evidence of hyperandrogenism
• Ultrasonographic evidence of a polycystic ovary
Phenotype 4 (nonhyperandrogenic PCOS) 18 %
• Evidence of oligo-anovulation
• Ultrasonographic evidence of a polycystic ovary
ELBOHOTY
22. Risks of women
with PCOS
should be part of
the management
• Metabolic consequences of PCOS
• NIDM
• Hypertension
• Obstructive sleep apnoea
• Developing cardiovascular disease (CVD)
• Endometrial cancer
• Anxiety and depression
• Psychosexual dysfunction
• Eating disorders and disordered eating
• During pregnancy:
• Miscarriage
• Gestational diabetes
• Preclampsia
23. Weight reduction in PCOS
• Dietary intervention:
• An energy deficit of 30% or 500 - 750 kcal/day
• Exercise intervention:
• A minimum of 250 min/week of moderate
intensity activities or
• 150 min/week of vigorous intensity
• Bariatric surgery:
• Women with a BMI> 40 Kg/m2 with no other
morbidities
• >35 kg/m2 with comorbidities, such as diabetes,
hypertension, OSA,…..
ELBOHOTY
25. AI (letrozole) versus CC
Gadalla et al., UOG 2018, Legro et al., N Engl J Med 2014: Casper et al,. Hum Reprod Update. 2008; Sharma et al.,
PLoS One. 2014
• No statistically differences in side effects or congenital malformations
• Many trials are reassuring about its safety towards the unborn babies
• Letrozole is a reasonable first-line agent for ovulation induction in PCOS
patients (World Health Organization guidance and ASRM 2017, ESHRE 2018)
3/18/20
Forest plot for comparison of live birth between CC and letrozole
ELBOHOTY
26. No need for Luteal support
Letrozole (2.5 mg)
(D2-6)
TVS TVS
Ovulation Trigger
250 Mcg
hCG
D2 D 6
Cochrane Review 2013; holzer H et al 2005. Fertil & sterility: Casper et al., J Clin Endocrinol Metab.
2006; The Practice Committee ASRM 2013. Fertil & Sterile, 100,2,341-348
Letrozole or CC regimen
One follicle >18
mm
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
3/18/20
C C (50 mg)
(D2-6)
Not to use for more than 6 months if ovulation occurs
ELBOHOTY
27. Premenstrual use: Clomiphen citrate or
Letrozole
Has a higher probability of ovulation and higher number
of mature follicles than the conventional use.
Elbohoty et al., J. Obstet. Gynaecol. Res. 2016 ; Badawy et al., Fertil Steril 2009
3/18/20
Menstrual
shedding
TVS TVS
Ovulation Trigger
250 μg hCG
Progesterone
withdrawal One follicle
>17mm
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
C C (50 mg) or
Letrozole2.5 MG
Before
menstruation
17
ELBOHOTY
29. Gonadotrophins
•For women with PCOS who have failed
to ovulate with first line oral ovulation
induction therapy
3/18/20 ELBOHOTY
30. low-dose step-up regimen is
recommended
25-37.5-50 IU FSH/day
Cycle
D
37.5- 75
IU FSH
250 μg
hCG
14- 21th D
7-14th D2nd day
>17mm
E2TVS
75- 112.5
IU FSH
TVS
E2
TVUS
TVUS
TVUS
TVUS
Luteal support
3/18/20
CANCEL THE CYCLE:
more than two follicles greater than 16–18 mm in mean
diameter are observed.
NO trigger and avoid intercourse.
ELBOHOTY
31. Technique
• NO more than four per
ovary for 4 seconds at 40
watts.
• Avoid the hilum & ovarian
ligament
• The instillation of 500–1000
ml of an isotonic solution
into the pouch of Douglas
cools the ovaries
An alternative: Laproscopic
ovarian drilling
ELBOHOTY
32. LOD versus OI with rFSH?
• Multicentre RCT in the Netherlands
• In which 168 CC-resistant women
Bayram et al., BMJ 2004
LOD OI with rFSH
Initial cumulative
pregnancy rate after 6
months
34% 67%
Time to conceive Took longer to conceive
and 54% required
additional medical
ovulation induction
therapy.
Less time to conceive
3/18/20 ELBOHOTY
34. When to refer PCOS
patient to IVF ?
3/18/20
•Where first or second line
ovulation induction therapies have
failed.
•If conception has failed to occur
after six to nine ovulatory cycles.
ELBOHOTY
35. Is there a role for IUI?
3/18/20
unexplained subfertility that under- went the same ovarian
stimulation in both arms.
mild male subfertility in unstimulated and in stimulated cycles.
Cochrane Database Syst Rev. 2016
NO
ELBOHOTY
37. AIM
to facilitate retrieval of multiple
oocytes without having complications
Fresh Transfer
+ freeze surpulus embryos
Freeze All
Or
+
38. Ideal number of retrieved oocytes
• For Fresh LBRs: 7-15.
• For Cumulative LBRs: the more
the better (70% when 25 oocytes
were retrieved)
(Sunkara et al, 2011; Polyzos et al,2018)
3/18/20 ELBOHOTY
39. Process of stimulation
3/18/20 ELBOHOTY
1. Down regulation
• Antagonist
• Agonist
• others
2. Ovarian stimulation
• Dose
• Type
3. Final maturation
• HCG
• GnRH
4. Luteal phase support
• Progesterone
• E+P
• HCG
• GnRH
40. The ovarian response can be expected by
• AMH or AFC
3/18/20 ELBOHOTY
Hyper
response
the retrieval of more
than 15 oocytes
Normal
response
the retrieval of 10 to
15 oocytes
Suboptimal
response
The retrieval of four to
nine oocytes
Poor
response
the retrieval of less
than four oocytes
• Previous response
In the first IVF cycle
41. Markers of ovarian response and dose
determination
AFC AMH Ovarian reserve Clinical
application
Gonadotrophin
Dose
0-4 <0.8 ng/ml Very low POR
5-8 0.8-1.5 ng/ml low Low response 225-300
9-19 1.5-4 ng/ml Normal Normal response 150-225 IU
20- > 4 ng/ml High Hyperresponse 112.5-150
3/18/20 ELBOHOTY
Martins et al.,
2015
42. Markers of ovarian response and dose
determination
AFC AMH Ovarian reserve Clinical
application
Gonadotrophin
Dose
0-4 <0.8 ng/ml Very low POR
5-8 0.8-1.5 ng/ml low Low response 225-300
9-19 1.5-4 ng/ml Normal Normal response 150-225 IU
20- > 4 ng/ml High Hyperresponse 112.5-150
3/18/20 ELBOHOTY
Martins et al.,
2015
53. Triggering
3/18/20 ELBOHOTY
• HCG:
• 5000 IU urinary HCG IM or
• 250 μg subcutaneously of
recombinant human chorionic
gonadotrophin (HCG)
OR
• Triptolin 0.2: in hyper responder
women with antagonist protocol + freeze
all or modified luteal support
• LH should be > 0.5 at start of
stimulation and at trigger day.
Criteria to trigger:
• when dominant follicles sizes between 16
and 22 mm in diameter.
54. Triggering
3/18/20 ELBOHOTY
• HCG:
• 5000 IU urinary HCG IM or
• 250 μg subcutaneously of
recombinant human chorionic
gonadotrophin (HCG)
OR
• Triptolin 0.2: in hyper responder
women with antagonist protocol + freeze
all or modified luteal support
• LH should be > 0.5 at start of
stimulation and at trigger day.
Criteria to trigger:
• when dominant follicles sizes between 16
and 22 mm in diameter.
55. Luteal phase support
ELBOHOTY 3/18/20
The luteal phase of all stimulated IVF cycles is abnormal (Edwards et al., 1980; Ubaldi et al., 1997; Macklon and
Fauser, 2000; Kolibianakis et al., 2003).
56. Should we give Luteal phase
support with simple induction ?
•Ovulation induction with
gonadotropins: YES
•Clomiphene citrate or
clomiphene plus
gonadotropins: NO
Katherine et al., Fertility and Sterility.VOL. 107 NO. 4 / APRIL 2017
3/18/20 ELBOHOTY
57. LUTEAL PHASE SUPPORT (Progesterone supplementation):
3/18/20 ELBOHOTY
Crinone gel 90 mg
One time per day
Cyclogest 200mg
suppositories
vaginal capules
(2 times per day)
Endometrin 100 mg
vaginal tablet
(3 times per day)
400 mg vaginal
pessary twice daily
Intramuscular 50 mg
One time per day
SC 25 mg daily
ESHRE, 2019
60. Risks of ovulation induction
3/18/20
Short term
Multiple
pregnancies
OHSS
Ovarian
torsion
Long term
ELBOHOTY
61. Risks •Multiple Gestation
• Simple induction:
• With CC treatment, approximately 8% overall
• With gonadotrophins:20 %.
• IVF: according to number of transferred embryos
•Ovarian Hyperstimulation Syndrome
3/18/20
• Ovarian torsion
• Its incidence is 0.1% and rises significantly with OHSS (2%) and
more rise in IVF pregnant patients with OHSS (16%)
ELBOHOTY
62. Risk of cancers
• Ovarian:
• Some studies have suggested that the risk of borderline ovarian tumors may be
increased (Kashyap et al., 2004; Liat et al., 2012).
• Other studies showed there is a strong relation to use of progesterone treatment not
ovarian stimulation (Bjørnholt etal., 2016)
• Breast cancer:
• Inconsistent results and more information on the subject is warranted.
• Endometrial cancers:
• Exposure to clomiphene citrate in subfertile women is associated with increased risk of
endometrial cancer, especially at doses greater than 2000 mg and high (more than 7)
number of cycles.
• This may largely be due to underlying risk factors such as polycystic ovary syndrome,
rather than exposure to the drug itself (Skalkidou et al., Cochrane Database Syst Rev
2017)
3/18/20 ELBOHOTY
64. •In anovular infertility patients; individualize the
intervention according to the cause and patient’s
characteristics
•In PCOS: Letrozole seems to be the 1st line
medication
•Gonadotrophins: 2nd line in PCOS with low dose
step up protocol aiming for monoovulation
•IVF is indicated for who are having ovulation for
more than 6 months without getting pregnancy
3/18/20 ELBOHOTY
65. •Antagonist protocol is the standard protocol
for ovarian stimulation for IVF.
•Individualized doses of gonadotrophins
according to expected response.
•Luteal phase support is not routine for
simple ovulation induction but is a
mandatory step with ovarian stimulation for
IVF.
3/18/20 ELBOHOTY
68. • WHO Scientific group, Geneva 1976, Report 514, Rowe et al, 1993
• NADIR R. FARID; Evanthia Diamanti-Kandarakis (26 March 2009). Diagnosis and Management of Polycystic Ovary Syndrome. Springer.
p. 243. ISBN 978-0-387-09717-6. Retrieved 5 September 2012.
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (January 2004). "Revised 2003 consensus on diagnostic criteria
and long-term health risks related to polycystic Fertil. Steril. 81 (1): 19–25. doi:10.1016/j.fertnstert.2003.10.004. PMID 14711538.
• Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (June 2004). "The prevalence and features of the polycystic ovary
syndrome in an unselected population". J. Clin. Endocrinol. Metab. 89 (6): 2745–2749. doi:10.1210/jc.2003-032046. PMID 15181052.
• Barbieri RL (November 2001). "The initial fertility consultation: recommendations concerning cigarette smoking, body mass index, and
alcohol and caffeine consumption". Am. J. Obstet. Gynecol. 185 (5): 1168–1173. doi:10.1067/mob.2001.117667. PMID 11717652
• Filicori M, Flamigni C, Dellai P, et al. (October 1994). "Treatment of anovulation with pulsatile gonadotropin-releasing hormone:
prognostic factors and clinical results in 600 cycles". J. Clin. Endocrinol. Metab. 79 (4): 1215–
1220. doi:10.1210/jc.79.4.1215. PMID 7962297
• Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC (July 1998). "Predictors of patients remaining anovulatory during
clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility". J. Clin. Endocrinol. Metab. 83 (7): 2361–
2365. doi:10.1210/jc.83.7.2361. PMID 9661609
• Crosignani PG, Ragni G, Parazzini F, Wyssling H, Lombroso G, Perotti L (March 1994). "Anthropometric indicators and response to
gonadotrophin for ovulation induction". Hum. Reprod. 9 (3): 420–3. PMID 8006129.
• Freundl G; Godehardt E; Kern PA; Frank-Herrmann P; Koubenec HJ; Gnoth Ch (December 2003). "Estimated maximum failure rates of
cycle monitors using daily conception probabilities in the menstrual cycle". Hum. Reprod. 18 (12): 2628 -
2633. doi:10.1093/humrep/deg488. PMID 14645183.
3/18/20 ELBOHOTY
69. • Misso, M. L. et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Human reproduction update 18, 301–312, doi:10.1093/humupd/dms003 (2012).
• Nugent, D., Vandekerckhove, P., Hughes, E., Arnot, M. & Lilford, R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. The Cochrane
database of systematic reviews, Cd000410. doi:10.1002/14651858.cd000410 (2000)
• Lord JM, Flight IH, Norman RJ (October 2003). "Metformin in polycystic ovary syndrome: systematic review and meta-analysis". BMJ. 327 (7421): 951–
0. doi:10.1136/bmj.327.7421.951. PMC 259161 . PMID 14576245.
• Kousta E, White DM, Franks S (1997). "Modern use of clomiphene citrate in induction of ovulation". Hum. Reprod. Update. 3 (4): 359–365. doi:10.1093/humupd/3.4.359. PMID 9459281.
• Medications for Inducing Ovulation from American Society for Reproductive Medicine. Revised 2012.
• Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R (2000). Nugent D, ed. "Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary
syndrome". Cochrane Database Syst Rev (4): CD000410. doi:10.1002/14651858.CD000410. PMID 11034687.
• Braat DD, Schoemaker R, Schoemaker J (February 1991). "Life table analysis of fecundity in intravenously gonadotropin-releasing hormone-treated patients with normogonadotropic and
hypogonadotropic amenorrhea". Fertil. Steril. 55 (2): 266–71. PMID 1991525.
• Boostanfar R, Jain JK, Mishell DR, Paulson RJ (May 2001). "A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction". Fertil. Steril. 75 (5):
1024–1026. doi:10.1016/S0015-0282(01)01749-6. PMID 11334921.
• Palomba S, Orio F, Nardo LG, et al. (October 2004). "Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome:
a prospective parallel randomized double-blind placebo-controlled trial". J. Clin. Endocrinol. Metab. 89 (10): 4801–4809. doi:10.1210/jc.2004-0689. PMID 15472166.
• Legro RS, Barnhart HX, Schlaff WD (2007). "Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome". N Engl J Med. 356 (6): 551–
566. doi:10.1056/NEJMoa063971. PMID 17287476.
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (March 2008). "Consensus on infertility treatment related to polycystic ovary syndrome". Fertil. Steril. 89 (3): 505–
522. doi:10.1016/j.fertnstert.2007.09.041. PMID 18243179.
• Johnson NP, Stewart AW, Falkiner J, et al. (April 2010). "PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with
Clomiphene". Hum Reprod. 25 (7): 1675–1683. doi:10.1093/humrep/deq100. PMID 20435692.
• 1982-95: a retrospective cohort study". Lancet. 354 (9190): 1579–1585. doi:10.1016/S0140-6736(99)04345-7. PMID 10560671.
• Fisk NM, Trew G (November 1999). "Two's company, three's a crowd for embryo transfer". Lancet. 354 (9190): 1572–1573. doi:10.1016/S0140-6736(99)00290-1. PMID 10560665.
• Eshre Capri Workshop Group (2003). "Mono-ovulatory cycles: a key goal in profertility programmes". Hum. Reprod. Update. 9 (3): 263–274. doi:10.1093/humupd/dmg020. PMID 12859047
• Albano, C.; Platteau, P.; Nogueira, D.; Cortvrindt, R.; Smitz, J.; Devroey, P. (2001). "Avoidance of multiple pregnancies after ovulation induction by supernumerary preovulatory follicular
reduction". Fertility and Sterility. 76 (4): 820–822. doi:10.1016/S0015-0282(01)02379-2. PMID 11591420.
3/18/20 ELBOHOTY
70. • Crosignani PG, Walters DE, Soliani A (1991) The ESHRE multicentre trial on the treatment of unexplained infertility: a preliminary report.
European Society of Human Reproduction and Embryology. Hum Reprod 6(7): 953-958.
• Guzick DS, Carson SA, Coutifaris C, Overstreet JW, Factor Litvak P, et al. (1999) Efficacy of superovulation and intrauterine insemination in the
treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med 340(3): 177-183.
• Goverde AJ, McDonnell J, Vermeiden JP, Schats R, Rutten FF, et al. (2000) Intrauterine insemination or in-vitro fertilisation in idiopathic
subfertility and male subfertility: a randomised trial and cost- effectiveness analysis. Lancet 355(9197): 13-18.
• Aboulghar MA, Mansour RT, Serour GI, Al Inany HG (2003) Diagnosis and management of unexplained infertility: an update. Arch Gynecol Obstet
267(4): 177-188.
• Skalkidou A1, Sergentanis TN2, Gialamas SP2, Georgakis MK2, Psaltopoulou T2, Trivella M3, Siristatidis CS4, Evangelou E5, Petridou E2 Cochrane
Database Syst Rev. Risk of endometrial cancer in women treated with ovary-stimulating drugs for subfertility. 2017 Mar 25;3:CD010931. doi:
10.1002/14651858.CD010931.pub2.
• Bayram N, van Wely M, Kaaijk EM, Bossuyt PMM, van der Veen F. Using an electrocautery strategy or recombinant FSH to induce ovulation in
polycystic ovary syndrome: a randomised controlled trial. BMJ 2004;328:192–5
• Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119
–129.
• Casper RF, Mitwally MF. A historical perspective of aromatase inhibitors for ovulation induction. Fertil Steril. 2012;98:1352– 1355.
• Requena A, Herrero J, Landeras J, et al. Use of letrozole in assisted reproduction: a systematic review and meta-analysis. Hum Reprod Update.
2008;14:571–582
• Sharma S, Ghosh S, Singh S, et al. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS
One. 2014;9:e108219.
• Katherine A. Green, M.D.,a Jessica R. Zolton, D.O.,a Sophia M. V. Schermerhorn, B.S.,b Terrence D. Lewis, M.D., Ph.D.,a,d Mae W. Healy, D.O.,a,d
Nancy Terry, M.L.S.,c Alan H. DeCherney, M.D.,a and Micah J. Hill, D.O.a Progesterone luteal support after ovulation induction and intrauterine
insemination: an updated systematic review and meta-analysis Fertility and Sterility.VOL. 107 NO. 4 / APRIL 2017
3/18/20 ELBOHOTY
71. • Bachelot A, Rouxel A, Massin N, Dulon J, Courtillot C, Matuchansky C, et al. Phenotyping and genetic studies of 357consecutive patients presenting with premature ovarian failure. EurJ
Endocrinol 2009;161:179–87. doi:10.1530/EJE-09-0231
• Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian
failure: a randomized, placebo-controlled trial. Fertil Steril 2007;87:858–61
• Lisa Marii, CookinghamLaxmi, A. Kondapall, Primary Ovarian Insufficiency pp 115-124| Noninvasive Approaches to Enhance Ovarian Function. 2016
• Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to
support the development of global WHO guidance). Hum Reprod Update 2016 Aug 10. DOI: 10.1093/ humupd/dmw025 [Epub ahead of print]
• Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary
syndrome. N Engl J Med 2014;371: 119–29.
• Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC,
Leppert PC, Myers ER for the Cooperative Multi- center Reproductive Medicine Network 2007 Clomiphene, metformin or both for infertility in the polycystic ovary
syndrome. N Engl J Med 356:551–566
• Elbohoty A, Amer M and Abdelmoaz M Clomiphene citrate before and after withdrawal bleeding for induction of ovulation in women with polycystic ovary syndrome: Randomized cross-
over trial. J. Obstet. Gynaecol. Res. 2016
• Badawy A, Inany H, Mosbah A, Abulatta M. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: A novel protocol. Fertil Steril 2009; 91: 838–
841.
• Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2006; 91:760–771. [PubMed: 16384846]
• Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary
syndrome. N Engl J Med 2014;371: 119–29.
• Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline Practice Committee of the American Society for Reproductive Medicine
American Society for Reproductive Medicine, Birmingham, Alabama, 2017.
• Insulin-sensitising drugs (metformin, rosiglitazone,pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility Lara C Morley, Thomas Tang,
Ephia Yasmin, Robert J Norman, Adam H Balen. Cochrane Database of Systematic Reviews, 2017, Issue 11. Art. No.: CD003053. DOI: 10.1002/14651858.CD003053.pub6
• Yiping Yu , Lanlan Fang, Ruizhe Zhang, Jingyan He, Yujing Xiong, Xiaoyi Guo, Qingyun Du, Yan Huang & Yingpu Sun. Comparative effectiveness of 9 ovulation-induction therapies in patients
with clomiphene citrate-resistant polycystic ovary syndrome: a network meta-analysis Scientific Reports 7, Article number: 3812(2017)
• Bordewijk EM1, Nahuis M2, Costello MF3, Van der Veen F4, Tso LO5, Mol BW6, van Wely M4. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or
intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2017 Jan 24;1:CD009090. doi: 10.1002/14651858.CD009090.pub2
• The Obstetrician & Gynaecologist Volume 18, Issue 2, pages 107-115, 13 FEB 2016 DOI: 10.1111/tog.12253 http://onlinelibrary.wiley.com/doi/10.1111/tog.12253/full#tog12253-fig-0001
3/18/20 ELBOHOTY
72. • Veltman-Verhulst SM, Hughes E, Ayeleke RO, Cohlen BJ. Intra-uterine
insemination for unex- plained subfertility. Cochrane Database Syst
Rev. 2016;2:CD001838.
• Jungwirth A, Diemer T, Dohle GR, Giwercman A, Kopa Z, Krausz C,
Tournaye H. Guideline on male infertility. Euro Assoc Urol. 2015.
http://uroweb.org/wp-content/uploads/17-Male- Infertility_LR1.pdf.
• Cissen M, Bensdorp A, Cohlen BJ, Repping S, de Bruin JP, van Wely M.
Assisted reproductive technologies for male subfertility. Cochrane
Database Syst Rev. 2016;2:CD000360.
3/18/20 ELBOHOTY